Search Result

Pathways Recommended:	Cell Cycle/DNA Damage

Results for "

Virus life cycle

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Influenza Virus (1) Biochemical Assay Reagents (1) Caspase (2) DNA/RNA Synthesis (1) EGFR (1) Enterovirus (1) SARS-CoV (1) Small Interfering RNA (siRNA) (2) Toll-like Receptor (TLR) (1)
By Research Areas:	Cardiovascular Disease (2) Infection (4) Inflammation/Immunology (2)
Oligonucleotides:	siRNAs (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Oligonucleotides

Targets Recommended: Influenza Virus Dengue virus Virus Protease

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-158820

Cosdosiran QPI-1007	Small Interfering RNA (siRNA) Caspase	Cardiovascular Disease
Cosdosiran is a chemically modified siRNA designed to temporarily inhibit expression of the caspase 2 protein and can be used for the study of nonarteritic anterior ischemic optic neuropathy and other optic neuropathies such as glaucoma that result in the death of retinal ganglion cells.?

HY-158820A

Cosdosiran sodium QPI-1007 sodium	Small Interfering RNA (siRNA) Caspase	Cardiovascular Disease
Cosdosiran sodium is a chemically modified siRNA designed to temporarily inhibit expression of the caspase 2 protein and can be used for the study of nonarteritic anterior ischemic optic neuropathy and other optic neuropathies such as glaucoma that result in the death of retinal ganglion cells.?

HY-E70364

IgdE protease	Biochemical Assay Reagents	Inflammation/Immunology
IgdE protease is a cysteine protease, which is initially isolated from Streptococcus agalactiae. IgdE protease digests monoclonal antibodies (mAbs) of the IgG1 type specifically at their upper hinge region, produces Fc/2, hinge peptide dimers, and Fab fragment. IgdE protease can be used in disulfide bonds and free thiol analysis, as it requires no reducing agents for cleavage .

HY-P0289

CEF3	Influenza Virus	Infection
CEF3 (SIIPSGPLK) corresponds to aa 13-21 of the influenza A virus M1 protein. The matrix (M1) protein of influenza A virus is a multifunctional protein that plays essential structural and functional roles in the virus life cycle.

HY-E70085

Moloney murine leukemia virus RT	DNA/RNA Synthesis	Infection
Moloney murine leukemia virus RT is a monomeric reverse transcriptase from Moloney murine leukemia virus (MMLV). Moloney murine leukemia virus RT is a replicative polymerase that play an essential role in the life cycle of the retrovirus .

HY-163377

AZ5385	Enterovirus EGFR	Infection
AZ5385 is an EGFR-tyrosine kinase inhibitor. AZ5385 is a HRV-2 virus blocker, with EC₅₀ of 0.35 µM. AZ5385 affects the late stage of viral life cycle .

HY-107202B

Polyinosinic-polycytidylic acid HMW Poly(I:C) HMW	Toll-like Receptor (TLR)	Inflammation/Immunology
Polyinosinic-polycytidylic acid HMW (Poly(I:C) HMW) is a synthetic double-stranded RNA (dsRNA) analogue that is produced during the replication life cycle of most viruses. Polyinosinic-polycytidylic acid HMW is a TLR3 receptor agonist .

HY-144798

FWM-5	SARS-CoV	Infection
FWM-5 is a potent NSP13 helicase inhibitor. SARS-COV-2 NSP13 helicase enzyme plays crucial role in the virus life cycle. FWM-5 has the potential for the research of infection diseases .

Cat. No.	Product Name

HY-L073

Anti-Hepatitis C Virus Compound Library	303 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 303 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Anti-Hepatitis C Virus Compound Library

303 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 303 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	Product Name	Target	Research Area

HY-P0289

CEF3	Influenza Virus	Infection
CEF3 (SIIPSGPLK) corresponds to aa 13-21 of the influenza A virus M1 protein. The matrix (M1) protein of influenza A virus is a multifunctional protein that plays essential structural and functional roles in the virus life cycle.

HY-P10497

EBV BZLF1 (190-197)	Peptides	Others
EBV BZLF1 (190-197) is an immunodominant CEF-controlling peptide derived from Epstein-Barr virus (EBV). EBV BZLF1 (190-197) is a suitable epitope for CD8+ T cells to stimulate the release of IFNg. CTL responses to EBV BZLF1 (190-197) are diverse and cross-recognize similar peptides from both host self-proteins and bacterial proteins. EBV BZLF1 (190-197) can be used to study autoimmune diseases .

CEF3	Infection Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields	Influenza Virus
CEF3 (SIIPSGPLK) corresponds to aa 13-21 of the influenza A virus M1 protein. The matrix (M1) protein of influenza A virus is a multifunctional protein that plays essential structural and functional roles in the virus life cycle.

Cat. No.	Product Name		Classification